Firestone Kareninsider trades
In SEC Form 4 filings, Firestone Karen is listed as Director of Amylyx Pharmaceuticals, Inc. (AMLX). Firestone Karen reported no open-market purchases or sales in the last 90 days. The latest Form 4 transaction on record was filed on Sep 2.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| AMLXAmylyx Pharmaceuticals, Inc. | Director | 4 | Sep 2 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-02
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals, Inc. | Aug 31 | Sep 2 | M | 25,000 | $1.76 | $44,000 | 91,900 | No | Form 4 |
| AMLXAmylyx Pharmaceuticals, Inc. | Aug 31 | Sep 2 | M | 25,000 | $5.05 | $126,250 | 116,900 | No | Form 4 |
| AMLXAmylyx Pharmaceuticals, Inc. | Aug 31 | Sep 2 | M · derivative | 25,000 | $1.76 | $44,000 | not reported | No | Form 4 |
| AMLXAmylyx Pharmaceuticals, Inc. | Aug 31 | Sep 2 | M · derivative | 25,000 | $5.05 | $126,250 | not reported | No | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.